Patient Resources / Clinical Trials
ImmusanT recently conducted an interim analysis of its global Phase 2 RESET CeD study to assess the safety, tolerability and efficacy of its lead therapeutic compound, Nexvax2, for patients with celiac disease. The results of this analysis showed that while Nexvax2 did not appear to have any notable safety issues, this approach did not provide protection from gluten exposure for patients when compared with placebo. As such, the company has made the difficult decision to discontinue the RESET CeD study.
We want to convey our sincere appreciation to all patients that participated in the RESET CeD clinical trial. Your important contributions have helped significantly advance our understanding of celiac disease and the science underlying this condition. While we did not achieve the desired outcome, we believe the study will generate valuable data that will help inform the field on improving treatment for patients with celiac disease.
We encourage you to remain hopeful and engaged in celiac disease research and continue to work closely with your medical providers to fully optimize your health.